newsfilter
← Latest News
PR Newswire·

Leap Therapeutics Acquires Flame Biosciences

Adds FL-301, clinical stage anti-Claudin18.2 antibody, and two preclinical antibody programs to Leap's pipeline Combined cash balance of approximately $115 million enhances runway to mid-2025, fully-funding